Workflow
天康生物2025年中报简析:营收净利润同比双双增长,盈利能力上升

Financial Performance - The company reported a total revenue of 8.847 billion yuan for the first half of 2025, representing a year-on-year increase of 10.68% [1] - The net profit attributable to shareholders reached 338 million yuan, up 22.27% year-on-year [1] - In Q2 2025, total revenue was 4.666 billion yuan, with a year-on-year increase of 10.68%, while net profit decreased by 14.59% to 190 million yuan [1] - The gross margin improved by 5.03% to 12.07%, and the net margin increased by 32.29% to 4.63% [1] - Total expenses (selling, administrative, and financial) amounted to 519 million yuan, accounting for 5.86% of revenue, a decrease of 13.04% year-on-year [1] Key Financial Ratios - Earnings per share (EPS) increased by 25% to 0.25 yuan [1] - Operating cash flow per share surged by 109.36% to 1.19 yuan [1] - The company's return on invested capital (ROIC) was 5.03%, indicating a generally weak capital return [3] - The net profit margin for the previous year was 3.47%, suggesting low added value for products or services [3] Debt and Cash Flow Analysis - The company had cash and cash equivalents of 2.973 billion yuan, a 3.87% increase year-on-year [1] - Interest-bearing liabilities decreased by 14.76% to 4.926 billion yuan [1] - The cash flow situation is a concern, with cash to current liabilities ratio at 59.75% [5] - The interest-bearing asset-liability ratio reached 30.33%, indicating a significant level of debt [5] Market Position and Investment Sentiment - The company has seen mixed performance in its historical financial reports, with two years of losses since its IPO [3] - Major funds have increased their holdings in the company, with the largest being Guotai CSI Livestock Breeding ETF, which holds 15.5491 million shares [6] - Analysts expect the company's performance for 2025 to reach 542 million yuan, with an average EPS forecast of 0.4 yuan [5]